Description
The goals of this project are to (1) describe the clinical pathway of genetic testing
at Palo Alto Medical Foundation (PAMF) and (2) to assess and obtain preliminary data
on the use of genetic tests at PAMF.
PI is Kathryn Phillips, Ph.D., University of California San Francisco. Site PI is Su-Ying Liang, Ph.D.
PI is Kathryn Phillips, Ph.D., University of California San Francisco. Site PI is Su-Ying Liang, Ph.D.
Principal Investigator
External PI, Principal Investigator, Su-Ying Liang, Ph.D.
Co-Investigator(s)
Funder
National Human Genome Research Institute / University of California San Francisco
Start Date
February 01, 2015
End Date
January 31, 2016
Research Topics
Related Studies
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Our objective is to examine “coverage, price, and reimbursement” for multigene tests
broadly and for cancer-related indications.
Investigator(s): Su-Ying Liang, Ph.D.
Genetics and Comorbidity of Migraine
Identify common genetic variants for migraine to determine whether there are single
nucleotide polymorphisms associated with migraine.
Investigator(s): Alice R. Pressman, Ph.D., M.S.
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
To describe and explain variations in Lynch syndrome (LS) screening implementation
across healthcare systems and create a toolkit for implementing LS screening.
Investigators: Su-Ying Liang, Ph.D., External PI, Principal Investigator
Precision Medicine for Multiple Sclerosis: Making It Work (MS-SHARE)
Develop an app that support access to clinical data and shared decision-making, predict
disease course, and guide disease management.
Investigators: J.B. Jones, PhD, MBA, Xiaowei (Sherry) Yan, PhD, MS
Understanding the Experiences of Patients Undergoing Genetic Counseling and Testing for BRCA
This project investigates how patients deliberate, decide, & act upon genetic counseling
& testing to determine their personal risk for breast & ovarian cancer.